Drug intelligence / Profile preview

18F-PSMA-7Q

Development stage
Unknown
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

18F-PSMA-7Q is a novel fluorine-18 labeled prostate-specific membrane antigen (PSMA) ligand developed as a PET imaging tracer for the detection and staging of prostate cancer. It binds specifically to PSMA, a transmembrane glycoprotein highly overexpressed in primary and metastatic prostate cancer cells. As a radiopharmaceutical, it enables high-resolution positron emission tomography/computed tomography (PET/CT) imaging of PSMA-expressing lesions, supporting diagnosis, staging, and recurrence assessment in patients with prostate cancer. Comparative studies have shown that 18F-PSMA-7Q provides similar lesion detection rates and biodistribution characteristics to other established PSMA-targeted tracers such as 18F-DCFPyL[1]. The agent is under clinical investigation for its diagnostic performance in newly diagnosed and recurrent prostate cancer.

Brand names
18F-PSMA-7Q
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 18F-PSMA-7Q.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-PSMA-7Q.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call